Climb Bio Inc (CLYM)

$9.26 -0.24 (-2.53%)
Market Cap 436.61M
Revenue (ttm) 0.00
Net Income (ttm) -59.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,688,200
Avg Vol 579,200
Day's Range N/A - N/A
Shares Out 47.77M
Stochastic %K 53%
Beta -0.21
Analysts Strong Sell
Price Target $16.25

Company Profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the syste...

Industry: Biotechnology
Sector: Healthcare
Phone: 866 857 2596
Address:
20 William Street, Suite 145, Wellesley Hills, United States
Tankman22
Tankman22 Apr. 28 at 2:33 PM
$CLYM $BIYA runners went crazy 🔥😈currently green in both of these stocks
0 · Reply
Tankman22
Tankman22 Apr. 28 at 2:23 PM
$CLYM back over 10$🔥 turned this into a swing for 11.50-13$ sell zone
0 · Reply
zenflow_yuj
zenflow_yuj Apr. 28 at 1:56 PM
$CLYM under the radar coil, sellers not leaning yet
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 28 at 1:56 PM
$CLYM Share Price: $9.86 Contract Selected: Nov 20, 2026 $10 Calls Buy Zone: $2.72 – $3.35 Target Zone: $4.82 – $5.89 Potential Upside: 68% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/
1 · Reply
Tankman22
Tankman22 Apr. 28 at 1:47 PM
$CLYM I can see 10$+ being the next level up, for sure 🔥 currently in $BIYA & got a W on $ATER & $SKYQ & $NEXR great way to start BULLS 😎🔥😈
0 · Reply
Tankman22
Tankman22 Apr. 28 at 12:40 PM
$CLYM after deep research I’m loving this stock to hold, might not be a day trade but this clearly is bullish & has room to 12$+ lovely 3 months gain already from 6$!!! $NEXR $SKYQ $ATER $BBBY
0 · Reply
OpenOutcrier
OpenOutcrier Apr. 28 at 12:34 PM
$CLYM (+4.9% pre) Climb Bio raises $110 million in private placement https://ooc.bz/l/100206
0 · Reply
Jaxion
Jaxion Apr. 28 at 12:22 PM
$CLYM watching this today.
0 · Reply
Tankman22
Tankman22 Apr. 28 at 11:55 AM
$CLYM still continue to creep back up definitely seems like oilers & Iran/israel war theme is back for today with $SKYQ $ANNA $SAFX $NEXR moving nice … it’s always one stock to run outside the theme
0 · Reply
Tankman22
Tankman22 Apr. 28 at 11:39 AM
$SAFX got some of this off $SKYQ … also in $CLYM i like this outside of oilers running rn 🔥😈 bulls let’s make this market HOT $MLEC $KIDZ
0 · Reply
Latest News on CLYM
Climb Bio, Inc. Announces $110.0 Million Private Placement

Apr 28, 2026, 7:00 AM EDT - 14 hours ago

Climb Bio, Inc. Announces $110.0 Million Private Placement

Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026

Apr 8, 2026, 7:00 AM EDT - 20 days ago

Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026

Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy

Apr 7, 2026, 7:00 AM EDT - 21 days ago

Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy

Climb Bio Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 2:20 PM EDT - 7 weeks ago

Climb Bio Transcript: Leerink Global Healthcare Conference 2026

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 5, 2026, 7:00 AM EST - 7 weeks ago

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Climb Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 1:20 PM EST - 2 months ago

Climb Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Climb Bio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 3:00 PM EST - 2 months ago

Climb Bio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Climb Bio to Present at Upcoming Investor Conferences

Feb 5, 2026, 7:00 AM EST - 2 months ago

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026

Jan 8, 2026, 7:00 AM EST - 3 months ago

Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026

Climb Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 9:30 AM EST - 5 months ago

Climb Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 25, 2025, 7:00 AM EST - 5 months ago

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 6, 2025, 7:01 AM EST - 6 months ago

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy

Oct 21, 2025, 7:00 AM EDT - 6 months ago

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025

Oct 17, 2025, 7:00 AM EDT - 6 months ago

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025

Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer

Oct 1, 2025, 7:00 AM EDT - 7 months ago

Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer

Climb Bio Transcript: Status Update

Sep 29, 2025, 8:00 AM EDT - 7 months ago

Climb Bio Transcript: Status Update

Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN

Sep 29, 2025, 7:00 AM EDT - 7 months ago

Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN

Climb Bio Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 16, 2025, 10:30 AM EDT - 8 months ago

Climb Bio Transcript: Stifel Virtual Immunology and Inflammation Forum

Climb Bio Transcript: Baird Global Healthcare Conference 2025

Sep 9, 2025, 4:20 PM EDT - 8 months ago

Climb Bio Transcript: Baird Global Healthcare Conference 2025

Climb Bio Transcript: Cantor Global Healthcare Conference 2025

Sep 5, 2025, 10:55 AM EDT - 8 months ago

Climb Bio Transcript: Cantor Global Healthcare Conference 2025

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

Sep 4, 2025, 7:00 AM EDT - 8 months ago

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences

Aug 25, 2025, 2:41 PM EDT - 8 months ago

UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences

Climb Bio to Present at Upcoming September 2025 Investor Conferences

Aug 25, 2025, 7:00 AM EDT - 8 months ago

Climb Bio to Present at Upcoming September 2025 Investor Conferences

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 12, 2025, 7:00 AM EDT - 9 months ago

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 14, 2025, 7:00 AM EDT - 1 year ago

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Climb Bio Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 10, 2025, 8:45 AM EDT - 1 year ago

Climb Bio Transcript: 24th Annual Needham Virtual Healthcare Conference

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Mar 25, 2025, 4:05 PM EDT - 1 year ago

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Climb Bio Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 10:00 AM EDT - 1 year ago

Climb Bio Transcript: Leerink Global Healthcare Conference 2025

Climb Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 9:50 AM EST - 1 year ago

Climb Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

Feb 24, 2025, 7:00 AM EST - 1 year ago

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

Climb Bio Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 9:20 AM EST - 1 year ago

Climb Bio Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 1 year ago

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Jan 9, 2025, 7:00 AM EST - 1 year ago

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Climb Bio to be Added to the Nasdaq Biotechnology Index

Dec 19, 2024, 7:00 AM EST - 1 year ago

Climb Bio to be Added to the Nasdaq Biotechnology Index

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 12, 2024, 4:05 PM EST - 1 year ago

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Climb Bio Appoints Douglas E. Williams, Ph.D.

Nov 11, 2024, 7:00 AM EST - 1 year ago

Climb Bio Appoints Douglas E. Williams, Ph.D.

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Oct 11, 2024, 12:30 PM EDT - 1 year ago

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Oct 4, 2024, 7:00 AM EDT - 1 year ago

Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Climb Bio to Host Virtual Investor Event on October 15, 2024

Oct 3, 2024, 10:00 AM EDT - 1 year ago

Climb Bio to Host Virtual Investor Event on October 15, 2024

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Oct 2, 2024, 9:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Eliem Therapeutics Announces Additions to its Leadership Team

Aug 26, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Additions to its Leadership Team

Eliem Therapeutics Reports Second Quarter Financial Results

Aug 14, 2024, 6:05 AM EDT - 1 year ago

Eliem Therapeutics Reports Second Quarter Financial Results

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Jun 27, 2024, 4:01 PM EDT - 1 year ago

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Climb Bio Transcript: M&A Announcement

Apr 11, 2024, 8:30 AM EDT - 2 years ago

Climb Bio Transcript: M&A Announcement

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Apr 11, 2024, 7:00 AM EDT - 2 years ago

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself

Jul 20, 2023, 6:57 AM EDT - 3 years ago

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

Jul 20, 2023, 6:45 AM EDT - 3 years ago

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

May 11, 2023, 4:10 PM EDT - 3 years ago

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Mar 6, 2023, 4:10 PM EST - 3 years ago

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Feb 9, 2023, 4:01 PM EST - 3 years ago

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

Nov 30, 2022, 7:00 AM EST - 3 years ago

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Nov 14, 2022, 6:10 AM EST - 3 years ago

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Nov 8, 2022, 7:00 AM EST - 3 years ago

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Eliem Therapeutics Provides Update on Pipeline Progress

Oct 5, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Provides Update on Pipeline Progress

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

Aug 15, 2022, 6:10 AM EDT - 4 years ago

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

Tankman22
Tankman22 Apr. 28 at 2:33 PM
$CLYM $BIYA runners went crazy 🔥😈currently green in both of these stocks
0 · Reply
Tankman22
Tankman22 Apr. 28 at 2:23 PM
$CLYM back over 10$🔥 turned this into a swing for 11.50-13$ sell zone
0 · Reply
zenflow_yuj
zenflow_yuj Apr. 28 at 1:56 PM
$CLYM under the radar coil, sellers not leaning yet
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 28 at 1:56 PM
$CLYM Share Price: $9.86 Contract Selected: Nov 20, 2026 $10 Calls Buy Zone: $2.72 – $3.35 Target Zone: $4.82 – $5.89 Potential Upside: 68% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/
1 · Reply
Tankman22
Tankman22 Apr. 28 at 1:47 PM
$CLYM I can see 10$+ being the next level up, for sure 🔥 currently in $BIYA & got a W on $ATER & $SKYQ & $NEXR great way to start BULLS 😎🔥😈
0 · Reply
Tankman22
Tankman22 Apr. 28 at 12:40 PM
$CLYM after deep research I’m loving this stock to hold, might not be a day trade but this clearly is bullish & has room to 12$+ lovely 3 months gain already from 6$!!! $NEXR $SKYQ $ATER $BBBY
0 · Reply
OpenOutcrier
OpenOutcrier Apr. 28 at 12:34 PM
$CLYM (+4.9% pre) Climb Bio raises $110 million in private placement https://ooc.bz/l/100206
0 · Reply
Jaxion
Jaxion Apr. 28 at 12:22 PM
$CLYM watching this today.
0 · Reply
Tankman22
Tankman22 Apr. 28 at 11:55 AM
$CLYM still continue to creep back up definitely seems like oilers & Iran/israel war theme is back for today with $SKYQ $ANNA $SAFX $NEXR moving nice … it’s always one stock to run outside the theme
0 · Reply
Tankman22
Tankman22 Apr. 28 at 11:39 AM
$SAFX got some of this off $SKYQ … also in $CLYM i like this outside of oilers running rn 🔥😈 bulls let’s make this market HOT $MLEC $KIDZ
0 · Reply
Prosperity_Partners
Prosperity_Partners Apr. 28 at 11:34 AM
$CLYM Climb Bio, Inc. Announces $110.0 Million Private Placement | Float: 39.5 M | IO: 73.89% | MC: 454 M
0 · Reply
Tankman22
Tankman22 Apr. 28 at 11:30 AM
$CLYM creeping back near VWAP it honestly does look like a great swing too let’s push bulls 😈😤 $SKYQ $ANNA $KIDZ $MLEC
0 · Reply
Tankman22
Tankman22 Apr. 28 at 11:26 AM
$SKYQ caught a W on this just not loading more of this $CLYM dip let’s get the market hot again bulls‼️😎🔥 $MLEC $KIDZ
0 · Reply
topstockalerts
topstockalerts Apr. 28 at 11:25 AM
$CLYM strong watch for today
0 · Reply
caracicatriz
caracicatriz Apr. 28 at 11:22 AM
$CLYM Phase 2 likely phenomenal leading to complete remission
0 · Reply
Olivia_Strickland
Olivia_Strickland Apr. 28 at 11:15 AM
$CLYM $110M PIPE announced overnight and the tape's actually rewarding it, +5.2% premarket to 9.99. Usually a placement at this size hits a $460M cap harder, but the name's already +102% in three months so the bid is treating this as fuel Source: https://tapeboard.com/chart/CLYM
0 · Reply
Tankman22
Tankman22 Apr. 28 at 11:14 AM
$CLYM entered riding this to 13+ bulls 😎🔥 private placement news $KIDZ $MLEC $HTCO $VSA
0 · Reply
dixiebull
dixiebull Apr. 28 at 11:08 AM
$CLYM
1 · Reply
DwigtMcDichael
DwigtMcDichael Apr. 28 at 11:05 AM
$CLYM https://ir.climbbio.com/news-releases/news-release-details/climb-bio-inc-announces-1100-million-private-placement
0 · Reply
HustlerTV
HustlerTV Apr. 28 at 11:04 AM
POLA Short squeeze coming and float getting locked $SKLZ $CHSN $CLYM $YDDL big news
0 · Reply
Chrissixdd
Chrissixdd Apr. 25 at 2:50 PM
been digging through the industry and $SLNO is in the cheaper bucket. $RCKT $ORIC $CLYM $DNA nearby too
0 · Reply
erevnon
erevnon Apr. 21 at 6:43 PM
Oppenheimer maintains Climb Bio $CLYM at Outperform and raises the price target from $10 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply